Navigation Links
Cardiome Announces Positive Interim Phase 2b Results for Oral Vernakalant and Engages Merrill Lynch as Strategic Advisor
Date:3/17/2008

n (n=537), which includes patients randomized who did not enter the maintenance phase of the study. During the dosing period under analysis, there was no difference in the incidence of serious adverse events between treatment groups. Potentially drug-related serious adverse events occurred in 1% of placebo patients, 2% of patients in the 150mg dosing group, 0% of patients in the 300mg dosing group and 1% of patients in the 500mg dosing group. There were no cases of drug-related "Torsades de Pointes", a well-characterized arrhythmia which is an occasional side effect of some current anti-arrhythmic drugs. There were 2 deaths during this period, both unrelated to vernakalant (oral), comprising a patient in the 150mg dosing group who died of cervical cancer at day 79, and a patient in the placebo group who died at day 86 after suffering an ischemic stroke.

"Our strategic intent with this study was to pave the way to Phase 3 and provide efficacy and safety data to support business discussions," said Bob Rieder, Chairman and Chief Executive Officer of Cardiome. "This strong interim data set clearly enables us to move forward in planning the Phase 3 program and continue our discussions with interested parties."

The double-blind, placebo-controlled, randomized, dose-ranging study was designed to explore safety and tolerability, pharmacokinetics and efficacy of vernakalant (oral) over 90 days of dosing in patients at risk of recurrent atrial fibrillation. Patients received a 150mg, 300mg or 500mg dose of vernakalant (oral) or placebo twice per day. After the first 3 days, patients still in atrial fibrillation were electrically cardioverted. Successfully cardioverted patients continued to receive vernakalant (oral) or placebo for the remainder of the 90-day trial and were monitored throughout the dosing period.

Cardiome initiated the Phase 2b in the first quarter of 2007. Enrollment has completed, with a total of 735 patients randomized of which approxim
'/>"/>

SOURCE Cardiome Pharma Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine news :

1. Cardiome And Astellas Announce Regulatory Update
2. Cardiome to Hold Investor Update Call
3. Cardiome Updates Guidance
4. Cardiome Initiates Phase 1 Study for GED-aPC
5. Cardiome To Release Third Quarter Results
6. Cardiome to Present at CIBC Conference
7. Cardiome to Present at ThinkEquity Conference
8. Cardiome to Present at Bear Stearns Conference
9. Weight Watchers Announces Election of Kim Roy to Board of Directors
10. MedQuist Announces Entry Into Settlement Term Sheet Resolving South Broward Litigation
11. Exelixis Announces March 19 Webcast of Presentation at the Lehman Brothers Annual Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... 2014 The 2014 Warrior-Family Symposium ... Reagan Building and International Trade Center in Washington, ... and Civilian Communities,” will be held from 8:30 ... a.m.) and cohosted by the Military Officers Association ... Association (NDIA). USAA is the Executive Sponsor of ...
(Date:7/22/2014)... By Steven Reinberg ... -- Two treatments that break up blood clots deep in ... of death risk. However, one results in a greater risk ... the cost of the other treatment, a new study finds. ... deep vein thrombosis (DVT) -- is blood-thinning medications and compression ...
(Date:7/22/2014)... minimally invasive hysterectomy using electric power morcellation, uterine cancers ... time of the procedure, according to a study published ... this procedure, in which the uterus is fragmented into ... malignancies. , Despite the commercial availability of electric power ... of malignancy at the time of electric power morcellation ...
(Date:7/22/2014)... -- The American Society of Hematology (ASH) will present ... Award for Lifetime Achievement in Hematology, to Kanti R. ... (LIJ) School of Medicine for his 50-year career combining ... mentoring, and exceptional patient care. , The Wallace ... bestowed on an individual who has been a vital ...
(Date:7/22/2014)... disorders may share certain pathogenic mechanisms with cancer, according ... researcher Linda Kusner, Ph.D. , published in ... shifting work shows that the very same inhibitors of ... in cells that produce autoimmune diseases. Henry Kaminski, ... the GW School of Medicine and Health Sciences (SMHS), ...
Breaking Medicine News(10 mins):Health News:2014 Warrior-Family Symposium Focuses on Transitioning Forward 2Health News:2014 Warrior-Family Symposium Focuses on Transitioning Forward 3Health News:Study Casts Doubt on Costly Treatment for Leg Clots 2Health News:Study Casts Doubt on Costly Treatment for Leg Clots 3Health News:Study examines presence of uterine cancers at the time of hysterectomy using morcellation 2Health News:ASH honors Kanti R. Rai, M.D., with Coulter Award for Lifetime Achievement 2Health News:ASH honors Kanti R. Rai, M.D., with Coulter Award for Lifetime Achievement 3Health News:ASH honors Kanti R. Rai, M.D., with Coulter Award for Lifetime Achievement 4Health News:New research finds pathogenic connection between autoimmune disorders and cancer 2
... and product launch in Southern California is an important stride to ... ... Americans -, TORRANCE, Calif., Sept. 24 Tokyo-based consumer,products company ... first mainstream market in the U.S.,This fall, the probiotic dairy drink will ...
... New findings from researchers at Wake Forest University ... with kidney failure can develop a rare tightening and ... lungs and heart. , Reporting in the October ... suggest a possible explanation for why some patients on ...
... 24 When the Deficit Reduction Act of,2005 ... state Medicaid programs,must demonstrate compliance with the requirement ... or risk losing federal,funding. Under tremendous pressure ... - 90 days, some states already are requiring ...
... Assessment of Impact Underway; Updated Results to Be ... Congress Considers Legislation to Ease Requirements, WASHINGTON, ... of the impact of Medicaid documentation requirements enacted ... of Public Health,and Health Services (GW SPHHS) compiled ...
... Inc. (NYSE: PRX ) invites investors and the,general ... update on the company,s,business strategy and results from 8:30 ... to the live webcast, visit the company,s website homepage ... link. A replay of the,meeting will be available approximately ...
... MetLife Foundation will,begin the next phase of its ... cooperation with the nonprofit Partnership,for a Drug-Free America(R) ... The radio campaign is backed by web resources ... features radio messages, in both English and Spanish,which ...
Cached Medicine News:Health News:Worldwide Probiotic Drink, Yakult(R), Launches in Its First Major U.S. Market 2Health News:New study suggests cause of debilitating skin condition 2Health News:ACM Helps Medicaid Programs Comply With Federal Deficit Reduction Act Mandates 2Health News:Community Health Centers Reveal Specific Ramifications of The Medicaid Citizenship and Identification Documentation Requirements 2Health News:Community Health Centers Reveal Specific Ramifications of The Medicaid Citizenship and Identification Documentation Requirements 3Health News:Community Health Centers Reveal Specific Ramifications of The Medicaid Citizenship and Identification Documentation Requirements 4Health News:MetLife Foundation Begins New Phase of Award-Winning Parenting Skills Campaign in Collaboration with the Partnership for a Drug-Free America(R) 2Health News:MetLife Foundation Begins New Phase of Award-Winning Parenting Skills Campaign in Collaboration with the Partnership for a Drug-Free America(R) 3Health News:MetLife Foundation Begins New Phase of Award-Winning Parenting Skills Campaign in Collaboration with the Partnership for a Drug-Free America(R) 4
(Date:7/22/2014)... , July 22, 2014  PuraMed BioScience®, Inc., ... over-the-counter (OTC) medicinal and healthcare products, announced today ... Operation Troop Aid. "We are pleased ... Mitchell , CEO and Chairman of PuraMed BioScience. ... in combat zones experience migraines much more frequently ...
(Date:7/22/2014)... YORK , July 22, 2014 /PRNewswire-iReach/ -- ... New York ), a nationally and ... for patients requiring reproductive assistance, is pleased to announce ... Corps and Compassionate Care Programs to recognize the sacrifices ... The Compassionate Corps Program will allow qualifying ...
(Date:7/22/2014)... WuXi PharmaTech (Cayman) Inc. (NYSE: WX ... company with operations in China and ... it will release financial results for the second quarter of ... August 13, 2014 (which will be Thursday morning, August 14, ... the investor relations section of the Company,s website at ...
Breaking Medicine Technology:PuraMed BioScience Partners with Operation Troop Aid to Sponsor Care Packages 2PuraMed BioScience Partners with Operation Troop Aid to Sponsor Care Packages 3Reproductive Medicine Associates of New York Collaborates with EMD Serono to Offer Treatment Assistance to Eligible Veterans and their Spouses 2Reproductive Medicine Associates of New York Collaborates with EMD Serono to Offer Treatment Assistance to Eligible Veterans and their Spouses 3WuXi PharmaTech Schedules Second-Quarter 2014 Earnings Release 2
... Buffalo Grove, Ill. , May 11 Solta Medical, Inc. (Nasdaq: ... they have reached an agreement resolving lawsuits involving certain Thermage® patents held by ... The lawsuit was ... in Delaware by Alma Lasers seeking a declaration that nine Thermage ...
... Korea , May 10 CrystalGenomics, Inc., a novel ... Ascending Dose) study for its novel antibiotic candidate, CG400549, has been ... , , ... targeting ENR (Enoyl-acyl carrier protein reductase, which is a critical enzyme ...
Cached Medicine Technology:Solta Medical and Alma Lasers Resolve Patent Lawsuits 2Solta Medical and Alma Lasers Resolve Patent Lawsuits 3CrystalGenomics Announces Successful Completion of a Phase I SAD Clinical Trial for CG400549, its Novel Antibiotic Candidate 2
... The CKX microscopes utilize the ... visibility and operability in cell ... cost-effective inverted microscope suited to ... of fields--from tissue culture and ...
Continuous rocking motion graphic display....
Stainless steel lockable wall display for up to 12 frames....
Omni labs carries an extensive line of frames, lenses, soft contacts, RGP lenses, and many other products and services. It supports Zeiss, American optical, Sola, Rodenstock, Zylowear, Eyewear design...
Medicine Products: